Arecor Therapeutics Plc · LSE:AREC
Arecor Therapeutics — Investor Presentation (October 2026)
30 slides from Arecor Therapeutics's investor presentation, October 2026
Slide 1: Investor Presentation
Investor Presentation October 2026
Slide 2: Legal notice
Legal notice This Presentation does not constitute, or form part of, nor is it intended to communicate, any offer, invitation, inducement or recommendation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or
Slide 3: Introduction to Arecor
Arecor Introduction to Are ct
Slide 4: Arecor is a clinical-stage biotech company
Arecor is a clinical-stage biotech company, developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.
Slide 5: Investment Highlights
Investment Highlights Best-in-class, concentrated, ultra-rapid-acting insulins • Addressing unmet patient need in multi-billion $ diabetes market • Designed lowering burden and improving outcomes by transforming Automated Insulin Delivery (AID) systems Opportunity to partner with multiple major insu
Slide 6: Arecor's Concentrated Ultra-Rapid Acting Insulins
Arecor’s Concentrated Ultra-Rapid Acting Insulins Driving the next generation of AID systems to reduce patient burden and improve outcomes Page 6 6
Slide 7: Transforming Patient Care for People Living with Diabetes
Transforming Patient Care for People Living with Diabetes Arecor potentially has the only concentrated ultra- rapid acting insulins that can enable pump use for high insulin users and catalyse next generation of longer Algorithm wear smaller AID systems Calculates insulin dose based on CGM CGM readi
Slide 8: The challenge that Arecor has overcome
The challenge that Arecor has overcome • As insulin concentration is increased, it slows down its absorption and glucose lowering profile • Arecor has overcome this as demonstrated clinically by AT278 (U500) superior PK/PD profile compared with Humulin-R U500 (U500) Clinically proven best-in-class,
Slide 9: What Will Drive Growth in the Adoption of AID Systems?
What Will Drive Growth in the Adoption of AID Systems? More Cost Effective Improved Outcomes For patients T1D and T2D who and payer Reduced have high daily Faster insulins enable insulin needs more aggressive Burden algorithms Patients want Cannot achieve 3-day wear Achieve higher Time- smaller, lon
Slide 10: No Concentrated Rapid-Acting Insulins Available for Use in AID Systems
There Are No Concentrated Rapid-Acting Insulins Available for Use in AID Systems Arecor’s platform of concentrated ultra-rapid acting insulins in combination with AID can drive significant adoption U100 insulin AT290 (U200) AT278 (U500) Not designed for high TDD insulin insulin and longer wear in AI
Slide 11: Longer 7-day Wear Currently Not Achievable for Almost All T2Ds
Longer 7-day Wear Currently Not Achievable for Almost All T2Ds and >50% of T1Ds even in largest capacity AID insulin cartridge In AID systems with currently available U100 insulin in a 3mL insulin cartridge % of US IIT T2Ds and T1Ds who CANNOT reach wear-time with the largest 3mL INSULIN PUMP CARTRI
Slide 12: Need for concentrated insulin increases as cartridge size decreases
Need for concentrated ultra-rapid insulin increases as AID insulin cartridge size decreases In AID systems with currently available U100 insulin in a 2mL insulin cartridge % of US IIT T2Ds and T1Ds who CANNOT reach desired wear-time with a 2mL INSULIN PUMP CARTRIDGE vs insulin concentration IIT T2Ds
Slide 13: New Era of AID Innovation Driving Need for Arecor's Insulins
New Era of AID Innovation Driving Need for Arecor’s Insulins Omnipod 6 MiniMed Flex Mobi twiist iLet Insulet MiniMed Tandem Sequel Beta Bionics • FDA approval for • 7-day wear US launch: • FDA T2D approval • twiist AID launched • iLet launched May 2023 Omnipod 5 T2D Aug Nov 2022 Feb 2025 Jul 2025 20
Slide 14: Arecor Clinical Data
Arecor Clinical Data Driving the next generation of AID systems to reduce patient burden and improve outcomes Page 14 14
Slide 15: AT247-101 Demonstrated PK/PD Superiority vs NovoRapid and Fiasp
AT247-101 (100 U/mL) Demonstrated PK/PD Superiority Compared with NovoRapid® (100 U/mL) and Fiasp® (100 U/mL) in T1D Patients Potential to allow clinically meaningful TIR improvement in combination with specifically tuned algorithms AT247 AT247 Fiasp Fiasp NovoRapid NovoRapid AT247 showed superiorit
Slide 16: AT278-102 Demonstrated PK/PD Superiority vs NovoRapid in T1D
AT278-102 (500 U/mL) Demonstrated PK/PD Superiority Compared with NovoRapid® (100 U/mL) in T1D Patients Potential to be insulin of choice for high insulin users and catalyse next generation of smaller, longer wear pumps AT278 AT278 NovoRapid NovoRapid AT278 showed superiority for onset of appearance
Slide 17: AT278-104 Demonstrated PK/PD Superiority in T2D with High BMI
AT278-104 (500 U/mL) Demonstrated PK/PD Superiority Compared with NovoRapid® (100 U/mL) & Humulin-R U500 in T2D Patients with High BMI Potential to be insulin of choice for high insulin users and catalyse next generation of smaller, longer wear pumps AT278 Baseline Corrected Serum Insulin Aspart and
Slide 18: AT278-104 Superior PK/PD Compared with NovoRapid
AT278-104 Demonstrated Superior PK/PD Compared with NovoRapid® with Clear Potential to Be the Only Insulin to Catalyse Development of Next-Generation Insulin Pump Therapy PK PD -24 min C 1/2max -25 min -5 min, appearance -5 min Insulin exposure Treatment ratio (95% CI) Glucose lowering effect Treatm
Slide 19: Summary of AT278-102 and -104 Phase 1 Clinical Results
Summary of AT278-102 and -104 Phase 1 Clinical Results Demonstrating superiority compared with NovoRapid® and Humulin-R U500® • AT278 demonstrates significantly superior accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 diabetes and high BMI • Confirms previ
Slide 20: Faster onset allows more aggressive algorithms and improved outcomes
Faster onset of AT247/AT278 allows more aggressive algorithms resulting in improved glycemic outcomes and move toward FCL Several in silico simulation studies performed – example below (University of Virginia) • FDA-approved simulator was used, both in hybrid closed loop (HCL – USS Virginia) and ful
Slide 21: Commercial Case
Commercial Case Driving the next generation of AID systems to reduce patient burden and improve outcomes Page 21 21
Slide 22: US Patients with Greatest Unmet Need Represent ~$3Bn Insulin TAM
US Patients with Greatest Unmet Need Represent ~$3Bn Insulin Revenue TAM today 1st Adopter TAM Open up access ~$3Bn and AID adoption Total Addressab ~$2Bn US tes Patients le be on ia B TAM) IIT D ($5 1 million PWDs on >100U/day cannot achieve 3-day 2 million 4 wear in current AID Additional growth o
Slide 23: Significant AID Growth Projected in the US and Globally
Significant AID Growth Projected in the US and Globally US AID market still significantly underpenetrated Global AID Market Sales1 US AID market $20bn opportunity $5.7B • Only ~1m PWD on IIT using an AID system in the US today $4.7B $4.0B • 4m PWD on IIT eligible for AID use $3.5B $3.3B $2.9B • Repr
Slide 24: Development & Regulatory Pathway
Development & Regulatory Pathway Driving the next generation of AID systems to reduce patient burden and improve outcomes Page 24 24
Slide 25: Pathway to FDA Regulatory Approval for Insulin-AID System
Pathway to FDA Regulatory Approval for Concentrated Ultra- Rapid Acting Insulin-AID System Positive interactions with the FDA confirming innovative Phase 2 clinical study design 2025 2026 2027 2028 2029 2030 Ph 2 CMC Ph 3 CMC BLA CMC &Regs Ph 3 CMC 10x scale up Transfer & 3x File on 3 PV & CTM & CTM
Slide 26: Oral Delivery of Peptides
Page 26 Oral Delivery of Peptides Large market opportunity starting with oral GLP-1 26
Slide 27: Overcoming the Challenge of Oral Peptide Delivery
Overcoming the Challenge of Oral Peptide Delivery Peptides and Permeation Enhancers Do Not Survive the Digestive System Leading to Low Oral Bioavailability permeation The Challenge enhancers Harsh pH & digestive enzymes Poor peptide stability due to Arecor Proprietary degradation by digestive proces
Slide 28: Oral Delivery Proof of Concept GLP-1
Oral Delivery Proof of Concept GLP-1 Over 800 peptides in development, but a limited number are delivered orally due to very low bioavailability (<1%) Status Next Steps 1 Positive results stabilising Non-clinical PK studies to bioavailability proof semaglutide in the Arecor of concept Go-No/Go deliv
Slide 29: Investment Highlights
Investment Highlights Best-in-class, concentrated, ultra-rapid-acting insulins • Addressing unmet patient need in multi-billion $ diabetes market • Designed lowering burden and improving outcomes by transforming Automated Insulin Delivery (AID) systems Opportunity to partner with multiple major insu
Slide 30: Thank You
Thank You Sarah Howell, CEO David Ellam, CFO Chesterford Research Park Little Chesterford CB10 1XL +44 1223 426 060 [email protected] www.arecor.com
Arecor Therapeutics — Investor Presentation (October 2026) on 6ix